Tag: CheckMate -331 trial

BMS’ Opdivo flops in CheckMate -331 trial in small cell lung cancer

pharmanewsdaily- October 15, 2018

Bristol-Myers Squibb (BMS) cancer drug Opdivo (nivolumab) failed to meet the primary endpoint of the phase 3 CheckMate -331 trial in small cell lung cancer ... Read More